Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term study of elafibranor in adults with primary biliary cholangitis
CTR20263949Phase 3Active
- Sponsor
- Ipsen
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elafibranor in primary biliary cholangitis (PBC), sponsored by Ipsen. Started Oct 2026; status: active.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20263949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263949.